Cost-effectiveness of venlafaxine for the treatment of major depression in hospitalized patients

Clinical Therapeutics

Volumn 18, Issue 2, 1996, Pages 347-358

  Priest, Robert G ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; HOSPITALIZATION; HUMAN; MEDICAL FEE; MONITORING; NEUROTOXICITY; PHARMACOECONOMICS; PRODUCTIVITY; QUALITY OF LIFE;

EID: 0029887009     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80015-4     Document Type: Article

References (37)

1. Montgomery SA. Prophylaxis in recurrent unipolar depression: New indication for treatment studies. J Psychopharmacol. 1989;3:47-53.
2. Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins L, Regier D, eds. Psychiatric Disorders in America. New York: The Free Press; 1991:53-80.
3. National Institute of Mental Health/National Institutes of Health Consensus Development Conference Statement. Mood disorders: Pharmacologic prevention of recurrences. Am J Psychiatry. 1985;142: 469-476.
4. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993; 54:405-418.
5. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry. 1994;164: 665-673.
6. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: Results from the Medical Outcomes Study. JAMA. 1989;262:914-919.
7. Stoudemire A, Frank R, Hedemark N, et al. The economic burden of depression. Gen Hosp Psychiatry. 1986;8:387-394.
8. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol. 1993;7: 191-195.
9. Burke MJ, Silkey B, Preskorn SH. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. J Clin Psychiatry. 1994; 55(Suppl A):42-52.
10. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clin Ther. 1994;16:715-730.
11. McCombs JS, Nichol MB, Stimmel GL, et al. The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a medicaid population. J Clin Psychiatry. 1990;51(Suppl):60-69.
12. Freemantle N, House A, Song F, et al. Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide. BMJ. 1994;309:249-253.
13. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics. 1994;5:249-264.
14. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry. 1995;56: 450-458.
15. Danjou P, Hackett D. Safety and tolerance profile of venlafaxine. Int Clin Psychapharmacol. 1995;10(Suppl 2):15-20.
16. Beasley CM Jr, Bosomworth JC, Wernicke JF. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull. 1990;26:18-24.
17. Dierick M, Ravizza L, Realini R. Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuro-Psychopharmacol Biol Psychiatry. 1996; 20:57-71.
18. Benkert O, Hackett D, Realini R, et al. A randomized, double blind, comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. Neuropsychopharmacology. 1994;10(Suppl):165S. Abstract.
19. Clerc GE, Ruimy P, Verdeau-Paillès J on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol. 1994;9:139-143.
20. Shrivastava RK, Cohn C, Crowder J, et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol. 1994;14:322-329.
21. Mendels J, Johnston R, Mattes J, Riesenberg R. Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993;29:169-174.
22. Mendlewicz J. Pharmacologic profile and efficacy of venlafaxine. Int Clin Psychopharmacol. 1995;10(Suppl 2):5-13.
23. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: A survival-analytical approach. Eur Neuropsychopharmacol. 1993;3:127-135.
24. Stassen HH, Angst J, Delini-Stula A. Severity at baseline and onset of improvement in depression. Meta-analysis of imipramine and moclobemide versus placebo. Eur Psychiatry. 1994;9:129-136.
25. Rickels K, Derivan A, Entsuah R, et al. Rapid onset of antidepressant activity with venlafaxine treatment. Depression. 1995; 3:146-153.
26. Kasper S, Lepine JP, Mendlewicz J, et al. Efficacy, safety, and indications for tricyclic and newer antidepressants. Depression. 1995;2:127-138.
27. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 1986;90:131-138.
28. Danish University Antidepressant Group. Paroxetine: A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord. 1990;18:289-299.
29. Anderson I, Tomenson B. A meta-analysis of the efficacy of selective serotonin reuptake inhibitors compared to tricyclic antidepressants in depression. Neuropsychopharmacology. 1994;10(Suppl):106S. Abstract.
30. Roose SP, Glassman AH, Attia E, Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry. 1994;151:1735-1739.
31. Nierenberg AA, Feighner JP, Rudolph R, et al. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419-423.
32. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994; 9:47-53.
33. Gross PF. Potential economic effects of a new antidepressant (venlafaxine) in treating major depressive disorder in France. Health Economics Monograph No. 62. Sydney, Australia: Institute of Health Economics and Technology Assessment; April 1994.
34. Gross PF. Potential economic impact of venlafaxine in the treatment of inpatients with major depressive disorder, France 1994. Health Economics Monograph No. 64. Sydney, Australia: Institute of Health Economics and Technology Assessment; April 1994.
35. Einarson TR, Arikian S, Sweeney S, Doyle J. A model to evaluate the cost-effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther. 1995;17:136-153.
36. Rudolph R, Derivan AT, Pederson R. Quality of life: Assessment in drug development. APA Annual Meeting. Washington, DC, May 1992. Abstract no. 201.
37. Pedersen RD, Pallay AG, Rudolph R. Measurement of general life function in antidepressant clinical trials. Qual Life Res. In press.